Cisatracurium Besylate Injection — FDA Drug Shortage
The FDA lists a drug shortage record for Cisatracurium Besylate Injection (injection) from Hospira, Inc., A Pfizer Company with status To Be Discontinued. The shortage was first posted on Sep 11, 2026.
Shortage details
- Status
- To Be Discontinued
- Company
- Hospira, Inc., A Pfizer Company
- Package NDC
- 0409-1098-02
- Dosage Form
- Injection
- Presentation
- Cisatracurium Besylate, Injection, 10 mg/5ml (2 mg/mL) Single Dose Vial (NDC 0409-1098-02)
- Initial Posting
- Sep 11, 2026